ODI Pharma Past Earnings Performance
Past criteria checks 0/6
ODI Pharma's earnings have been declining at an average annual rate of -13.7%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 71.4% per year.
Key information
-13.7%
Earnings growth rate
-10.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 71.4% |
| Return on equity | -194.9% |
| Net Margin | -485.0% |
| Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ODI Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -4 | 6 | 0 |
| 30 Sep 23 | 1 | -7 | 6 | 0 |
| 30 Jun 23 | 0 | -7 | 6 | 0 |
| 31 Mar 23 | 0 | -7 | 6 | 0 |
| 31 Dec 22 | 0 | -8 | 8 | 0 |
| 30 Sep 22 | 0 | -8 | 7 | 0 |
| 30 Jun 22 | 0 | -7 | 7 | 0 |
| 31 Mar 22 | 1 | -7 | 7 | 0 |
| 31 Dec 21 | 0 | -5 | 4 | 0 |
| 30 Sep 21 | 0 | -4 | 4 | 0 |
| 30 Jun 21 | 0 | -4 | 4 | 0 |
| 31 Mar 21 | 0 | -3 | 7 | 0 |
| 31 Dec 20 | 0 | -5 | 7 | 0 |
| 30 Sep 20 | 0 | -6 | 6 | 0 |
| 30 Jun 20 | 0 | -5 | 5 | 0 |
| 31 Mar 20 | 0 | -5 | 3 | 0 |
| 31 Dec 19 | 0 | -3 | 1 | 0 |
| 30 Sep 19 | 0 | -3 | 2 | 0 |
Quality Earnings: ODI is currently unprofitable.
Growing Profit Margin: ODI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ODI is unprofitable, and losses have increased over the past 5 years at a rate of 13.7% per year.
Accelerating Growth: Unable to compare ODI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ODI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3%).
Return on Equity
High ROE: ODI has a negative Return on Equity (-194.91%), as it is currently unprofitable.